Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
61-75 of 4347 results
UK Prime Minister unveils plans to tackle prostate cancer
By PBR Staff Writer
UK Prime Minister Theresa May has announced £75m of funding to support new research for early diagnosis and treatment of prostate cancer.
Contract Research & Services > Clinical Trials > News
AbbVie’s upadacitinib succeeds in phase 3 rheumatoid arthritis trial
By PBR Staff Writer
AbbVie’s rheumatoid arthritis drug upadacitinib (15mg, once-daily) has met its primary and secondary endpoints in the phase 3 Select-Compare clinical study.
Contract Research & Services > Clinical Trials > News
Incyte and Merck's melanoma combo therapy fails in phase 3 trial
By PBR Staff Writer
A phase 3 study of Incyte’s epacadostat in combination with Merck’s Keytruda (pembrolizumab) in patients with unresectable or metastatic melanoma has failed meet to primary endpoint.
Contract Research & Services > Clinical Trials > News
Eli Lilly's Cyramza meets primary endpoint in phase 3 liver cancer trial
By PBR Staff Writer
Eli Lilly’ liver cancer treatment Cyramza (ramucirumab) has met its primary endpoint of overall survival (OS) and the secondary endpoint of progression-free survival (PFS) in the phase 3 Reach-2 study.
Contract Research & Services > Clinical Trials > News
MyoKardia begins dosing in phase 2 HCM trial of Mavacamten
MyoKardia has started dosing in its phase 2 MAVERICK-HCM clinical trial of mavacamten, the company’s oral, allosteric modulator of cardiac myosin mavacamten candidate in symptomatic non-obstructive hypertrophic cardiomyopathy patients.
Contract Research & Services > Clinical Trials > News
Sellas’ NeuVax + Herceptin combination treatment shows significant effect in breast cancer trial
Sellas Life Sciences Group has reported a positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin) +/- nelipepimut-S (NeuVax™) in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.
Contract Research & Services > Clinical Trials > News
Pfizer’s tafamidis meets primary endpoint in phase 3 transthyretin cardiomyopathy study
Pfizer sad its Tafamidis phase 3 transthyretin cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months
Contract Research & Services > Clinical Trials > News
MediciNova’s MN-001 meets primary end point in NASH / NAFLD study
By PBR Staff Writer
MediciNova said its MN-001 (tipelukast) has met its primary endpoint of reducing mean serum triglycerides in the phase 2 clinical trial of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia.
Contract Research & Services > Clinical Trials > News
Redx Pharma temporarily stops RXC004 cancer trial
By PBR Staff Writer
UK-based Redx Pharma is temporarily stopping the phase 1/2a clinical study of a cancer candidate, RXC004, to rectify the dose-escalation procedure and restart at a lower dose levels.
Contract Research & Services > Clinical Trials > News
Protagonist Therapeutics stops ulcerative colitis trial of PTG-100
Protagonist Therapeutics said it is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).
Contract Research & Services > Clinical Trials > News
Ablynx’s vobarilizumab fails to meet primary endpoint in phase II lupus study
By PBR Staff Writer
Ablynx’s lupus erythematosus treatment vobarilizumab has failed to meet primary endpoint in the phase II dose-ranging study.
Contract Research & Services > Clinical Trials > News
Mitsubishi Tanabe, Hitachi to use AI for improving efficiency of clinical trials
Mitsubishi Tanabe Pharma has partnered with Hitachi to improve the efficiency of clinical trials for the development of new drugs through the latter's artificial intelligence (AI) technology.
Contract Research & Services > Clinical Trials > News
Roche's lung cancer combination drug shows significant survival benefit
By PBR Staff Writer
Roche has announced that its Tecentriq (atezolizumab) combined with Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) showed a clinically significant survival benefit in a phase III lung cancer study.
Contract Research & Services > Clinical Trials > News
Pfizer's smoking cessation drug fails to meet primary endpoint in phase 4 study
By PBR Staff Writer
Pfizer said its smoking cessation drug Chantix/Champix (varenicline) has failed to achieve its primary endpoint in a phase 4 study.
Contract Research & Services > Clinical Trials > News
AbbVie not to seek accelerated approval for Rova-T after weak phase 2 SCLC trial data
By PBR Staff Writer
AbbVie has dropped plans to seek accelerated approval for Rova-T (rovalpituzumab tesirine) in the US in third-line relapsed/refractory (R/R) small cell lung cancer (SCLC) following disappointing results in a phase 2 trial.
Contract Research & Services > Clinical Trials > News
61-75 of 4347 results